ارقوتامین: نوسخه‌لر آراسینداکی فرق

| bioavailability = Intravenous: 100%,<ref name="kinetics1">{{cite journal|last=Sanders|first=SW|author2=Haering N |author3=Mosberg H |author4=Jaeger H |title=Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing|url=https://archive.org/details/sim_european-journal-of-clinical-pharmacology_1986-05_30_3/page/331|journal=Eur J Clin Pharmacol|date=1986|volume=30|issue=3|pages=331–4|doi=10.1007/BF00541538|pmid=3732370}}</ref> <br />Intramuscular: 47%,<ref name="kinetics2">Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313–22.</ref><br />Oral: <1%<ref>Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. '''Br J Clin Pharmacol''' 1983; 16: 695–9.</ref> (Enhanced by co-administration of caffeine<ref name="kinetics1" />)